Erlotinib

Common brands: Avastin, Carboplatin, Kyxata, Gemcitabine, Avgemsi

Top reporter: Armas Pharmaceuticals Inc.

Kinase Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitor [EPC]Platinum-based Drug [EPC]Microtubule Inhibitor [EPC]Folate Analog Metabolic Inhibitor [EPC]
9,597
Total Reports
5,214
Serious Reports
4,329
Death Reports
30
Reported Reactions
Death Report Ratio: High (45.11%)

Patient Demographics

Male
3,918
Female
4,100

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Erlotinib.

# Reaction Reports % of Total
1 DEATH 2,896
20.4%
2 RASH 1,069
7.5%
3 DIARRHOEA 1,007
7.1%
4 OFF LABEL USE 795
5.6%
5 MALIGNANT NEOPLASM PROGRESSION 766
5.4%
6 FATIGUE 582
4.1%
7 NAUSEA 540
3.8%
8 DRUG RESISTANCE 465
3.3%
9 VOMITING 451
3.2%
10 DISEASE PROGRESSION 445
3.1%
11 ASTHENIA 378
2.7%
12 DECREASED APPETITE 374
2.6%
13 DYSPNOEA 353
2.5%
14 MALAISE 352
2.5%
15 ANAEMIA 342
2.4%
16 DRUG INEFFECTIVE 335
2.4%
17 PNEUMONIA 285
2.0%
18 PAIN 265
1.9%
19 PYREXIA 251
1.8%
20 DEHYDRATION 243
1.7%
21 WEIGHT DECREASED 236
1.7%
22 NEUTROPENIA 226
1.6%
23 HYPERTENSION 218
1.5%
24 ABDOMINAL PAIN 211
1.5%
25 COUGH 206
1.5%
26 PLEURAL EFFUSION 190
1.3%
27 DERMATITIS ACNEIFORM 183
1.3%
28 CONSTIPATION 179
1.3%
29 DRY SKIN 165
1.2%
30 THROMBOCYTOPENIA 165
1.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.